New protein drugs to block Staph (S. aureus) infections
DARPin-based therapeutics against S. aureus infection
This project makes small engineered proteins (DARPins) that stop Staph bacteria from hiding in blood clots, with the goal of preventing or treating dangerous Staph infections like MRSA.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Texas A&m University Health Science Ctr NIH-funded |
| Lab location | 1 site (College Station, United States) |
| Project ID | NIH-11263744 on NIH RePORTER |
What this research studies
You would hear that researchers are designing tiny engineered proteins called DARPins to stick to a Staph surface protein (ClfA) so the bacteria cannot bind fibrin and form protective clots. They will test these DARPins in lab experiments and in mouse infection models of sepsis, septic arthritis, and endocarditis to see if the tools reduce clumping and disease severity. The team will optimize the molecules for potency and safety so they could eventually be developed into human treatments. If those steps go well, the next phases would aim toward clinical testing in people.
Who could benefit from this research
Good fit: People with recurrent or severe Staphylococcus aureus infections—such as MRSA bloodstream infections, septic arthritis, or endocarditis—would be the most likely candidates for future related trials.
Not a fit: This approach is unlikely to help infections caused by bacteria other than S. aureus or non‑infectious conditions, and it is still at a preclinical stage so immediate patient benefit is unlikely.
Why it matters
Potential benefit: If successful, this could produce a new type of treatment that prevents Staph from hiding in clots and helps clear infections, including antibiotic-resistant strains like MRSA.
How similar studies have performed: Related work blocking ClfA or similar Staph adhesins has shown protection in animal models but has not yet produced an approved human therapy, so the approach is promising but still experimental.
Where this research is happening
College Station, United States
- Texas A&m University Health Science Ctr — College Station, United States (Active)
Researchers
- Principal investigator: Chen, Zhilei — Texas A&m University Health Science Ctr
- Study coordinator: Chen, Zhilei
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.